HAB HIV Core Clinical Performance Measures: 

Adult/Adolescent Clients Group 2

Performance Measure: TB Screening OPR-Related Measure: No 

Percentage of clients with HIV infection who received testing with results documented for latent tuberculosis 

infection (LTBI) since HIV diagnosis

Numerator: 

Number of clients who received documented testing for LTBI with any approved test 

(tuberculin skin test [TST] or interferon gamma release assay [IGRA]) since HIV 

diagnosis 

Denominator: 

Number of HIV-infected clients who: 

• do not have a history of previous documented culture-positive TB disease or previous 

documented positive TST or IGRA1; and 

• had a medical visit with a provider with prescribing privileges2

 at least once in the 

measurement year. 

Patient 

Exclusions None 

Data Element: 

1. Is the client HIV-infected? (Y/N) 

a. If yes, has the client ever had previous documented culture-positive TB 

disease or previous documented positive TST or IGRA? (Y/N) 

i. If no, has the client ever been tested for LTBI with a TST or 

IGRA since his/her HIV diagnosis? (Y/N) 

1. If yes, are the results documented? (Y/N) 

Data Sources: 

• Ryan White Program Data Report, Section 5, Item 47 may provide data useful in 

establishing a baseline for this performance measure 

•Electronic Medical Record/Electronic Health Record 

•CAREWare, Lab Tracker or other electronic data base 

•HIVQUAL reports on this measure for grantee under review 

•Medical record data abstraction by grantee of a sample of records. 

National Goals, 

Targets, or 

Benchmarks 

for 

Comparison 

National HIVQUAL Data:3

2003 2004 2005 2006 

Top 10% 88.9% 91.7% 88.8% 92.2% 

Top 25% 77.4% 73.5% 74.8% 78.2% 

Mean* 58.8% 56.0% 57.1% 56.2% 

*from HAB data base 

Outcome 

Measures for 

Consideration 

° Incidence of TB disease in the clinic population 

Basis for Selection and Placement in Group 2: 

HIV is the most important known risk factor for progression to TB disease from latent TB infection (LTBI) 

after exposure to infectious TB patients. There is a 2% to 8% TB risk per year within 5 years after LTBI for 

HIV-infected adults4,5 versus an 8% TB risk over 60 years for adults with LTBI but not HIV6

. The TB risk for 

HIV-infected persons remains higher than for HIV-uninfected persons, even for HIV-infected persons who 

are taking antiretroviral medications.7,8 TB disease is an AIDS-defining opportunistic condition that can be 

deadly. McCombs found a 3 times adjusted odds of being diagnosed with TB at death and a 5 times adjusted 

August 1, 2008 Page 19 
HAB HIV Core Clinical Performance Measures: 

Adult/Adolescent Clients Group 2

odds of dying during TB treatment for HIV-infected TB patients compared with other patients from 1993 

through 2001.9 Immunologic and virologic evidence now indicates that the host immune response to M. 

tuberculosis enhances HIV replication and might accelerate the natural progression of HIV infection.10

Providers should screen all HIV infected patients for TB and LTBI as soon as possible after HIV diagnosis. 

TB and LTBI testing should be conducted among HIV-infected persons regardless of duration of infection 

since they are at increased risk for progressing to TB disease. Thus, an HIV-infected person having a prior 

positive TST for which he/she did not complete treatment is still eligible for treatment. However, early 

identification and treatment of TB disease improves outcomes and reduces the risk of transmission. TB 

should be suspected in any patient who has had a persistent cough for more than 2 to 3 weeks, especially if 

the patient has at least one additional symptom, including fever, night sweats (sufficient to require changing 

of bed clothes or sheets), weight loss, or hemoptysis (coughing up blood). Identification of LTBI and 

completion of LTBI treatment reduces the risk of development of TB disease by 70 to 90 percent.11

Measure reflects important aspect of care that impacts HIV-related morbidity and mortality and focuses on 

treatment decisions that affect a sizable population. Measure has a strong evidence base supporting the use.

US Public Health Guidelines: 

Guidelines for TB services for HIV-infected persons, such as those jointly published by the Public Health 

Service and the Infectious Diseases Society of America12 or by the Centers for Disease Control and 

Prevention (CDC)13 call for: 

• provision of a TST when HIV infection is first recognized, 

• annual or periodic TSTs for HIV-infected persons who are initially TST-negative and belong to 

groups at substantial risk for TB exposure or if they experience immune reconstitution, 

• chest radiographs and clinical evaluations to rule out active TB among those who are TST positive 

(reactions ≥ 5 mm) or who have symptoms (regardless of TST result), and 

• LTBI treatment (once active TB has been excluded) for those having a positive TST or for those who 

are recent contacts of persons with infectious active TB14. 

References/Notes:

1

Previous documented culture-positive TB disease or previous documented positive TST or IGRA occurred 

prior to HIV diagnosis. 

2

A “provider with prescribing privileges” is a health care professional who is certified in their jurisdiction to 

prescribe ARV therapy. 

3

”PPD screening” 

(http://www.hivguidelines.org/admin/files/qoc/hivqual/proj%20info/HQNatlAggScrs3Yrs.pdf

4

Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIVinfected persons. Annals of Internal Medicine. 1997;126:123-32. 

5

Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous 

drug users with human immunodeficiency virus infection. New England Journal of Medicine. 1989;320:545-

50. 

6

Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians 

and Alaska Natives: A 60-year follow-up study. Journal of the American Medical Association. 

2004;291(17):2086-91. 

7

The Antiretroviral therapy cohort collaboration. Incidence of tuberculosis among HIV-infected patients 

receiving highly active antiretroviral therapy in Europe and North America. Clinical Infectious Diseases. 

2005;41:1772-1782. 

August 1, 2008 Page 20 
HAB HIV Core Clinical Performance Measures: 

Adult/Adolescent Clients Group 2

8

Jones JL, Hanson DL, Dworkin MS, DeCock KM, and the Adult/Adolescent Spectrum of HIV Disease 

Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. International Journal of 

TB and Lung Disease. 2000;4(11):1026-1031. 

9

McCombs SB. Tuberculosis mortality in the United States, 1993-2001. Oral presentation at CDC. Atlanta. 

December 2003. 

10 Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients 

infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR 

Recomm Rep 1998 Oct 30;47(RR-20):1-58. 

11American Thoracic Society/Centers for Diseases Control and Prevention/Infectious Diseases Society of 

America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662 

12 Centers for Disease Control and Prevention. Guidelines for Preventing Opportunistic Infections Among 

HIV-Infected Persons — 2002 Recommendations of the U.S. Public Health Service and the Infectious 

Diseases Society of America. MMWR 2002;51 (No. RR-8) (http://www.cdc.gov/mmwr/PDF/rr/rr5108.pdf or 

http://aidsinfo.nih.gov/ContentFiles/OIpreventionGL.pdf) 

13 Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients 

infected with human immunodeficiency virus: Principles of therapy and revised recommendations. MMWR 

Recomm Rep 1998 Oct 30;47(RR-20):1-58. 

14Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis Recommendations 

from the National Tuberculosis Controllers Association and CDC. MMWR December 16, 2005 / Vol. 54 / 

No. RR-15 

August 1, 2008 Page 21